Table 2.
Univariate analysis | ||||||
---|---|---|---|---|---|---|
|
||||||
3-year overall survival | 3-year disease-free survival | |||||
|
||||||
HR | 95% CI | P-value | HR | 95% CI | P-value | |
CAFs density | 0.039 | 0.405 | ||||
CAF-poor | 1.000 | Ref. | - | 1.000 | Ref. | - |
CAF-rich | 1.870 | 1.033-3.385 | 0.039 | 1.258 | 0.733-2.160 | 0.405 |
Differentiation grade | 0.558 | 0.470 | ||||
Well | 1.000 | Ref. | - | 1.000 | Ref. | - |
Moderate | 1.450 | 0.699-3.009 | 0.318 | 1.303 | 0.660-2.575 | 0.446 |
Poor | 1.456 | 0.658-3.207 | 0.351 | 1.573 | 0.763-3.243 | 0.219 |
Tumor location | 0.359 | 0.426 | ||||
Upper | 1.000 | Ref. | - | 1.000 | Ref. | - |
Middle | 2.046 | 0.767-5.460 | 0.153 | 0.780 | 0.327-1.866 | 0.577 |
Low | 1.296 | 0.659-2.550 | 0.452 | 0.558 | 0.213-1.464 | 0.236 |
pN status | 0.041 | 0.100 | ||||
pN0 | 1.000 | Ref. | - | 1.000 | Ref. | - |
pN1 | 1.772 | 0.900-3.491 | 0.098 | 1.317 | 0.693-2.504 | 0.401 |
pN2 | 2.534 | 1.121-5.729 | 0.025 | 2.034 | 0.922-4.486 | 0.078 |
PN3 | 3.557 | 1.060-11.938 | 0.040 | 3.450 | 1.042-11.427 | 0.043 |
pTNM stage | 0.012 | 0.072 | ||||
I | 1.000 | Ref. | - | 1.000 | Ref. | - |
II | 7.830 | 1.053-58.244 | 0.044 | 1.442 | 0.586-3.550 | 0.426 |
III | 13.730 | 1.854-101.702 | 0.010 | 2.441 | 0.989-6.025 | 0.053 |
Radicality | 0.048 | 0.070 | ||||
R0 | 1.000 | Ref. | - | 1.000 | Ref. | - |
R1 | 3.424 | 0.813-14.432 | 0.094 | 2.363 | 0.568-9.837 | 0.237 |
R2 | 7.154 | 0.933-54.842 | 0.058 | 8.296 | 1.069-64.351 | 0.043 |
Adjuvant therapy | 0.449 | 0.215 | ||||
No | 1.000 | Ref. | - | 1.000 | Ref. | - |
Yes | 1.252 | 0.700-2.236 | 0.449 | 1.412 | 0.818-2.438 | 0.215 |
Abbreviations: N, pathological node stage; TNM, tumor node metastasis; CAFs, Cancer-associated fibroblasts; HR, hazard ratio; CI, confidence interval. Analysis was performed using the Cox proportion hazard model. P-value < 0.05 was considered significant.